
Citius Oncology, Inc.
CTORHealthcare|Medical - Pharmaceuticals|US
$0.51
+0.01 (+1.88%)
DCF Value
$0.10
Cash / Share
$0.15
Next Earnings Report
Dec 17, 2026
EPS est. -$0.07 · Revenue est. $3.3M
Financing Filings (last 12 months)
7
Shelf registrations / offering prospectuses — latest Jun 1, 2026 (424B3). Possible dilution.
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Recent Press Releases
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Nov 4, 2026 · PRNewsWire
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Oct 26, 2026 · PRNewsWire
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Oct 12, 2026 · PRNewsWire
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Sep 3, 2026 · PRNewsWire
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Aug 14, 2026 · PRNewsWire
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Aug 14, 2026 · PRNewsWire
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
Aug 12, 2026 · PRNewsWire
SEC Filings (77)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 4, 2026 | 8-K | Material event | DocumentIndex |
| Oct 26, 2026 | 8-K | Material event | DocumentIndex |
| Oct 23, 2026 | 8-K | Material event | DocumentIndex |
| Jun 1, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| Jun 1, 2026 | 8-K | Material event | DocumentIndex |
| May 29, 2026 | DEF 14C | DocumentIndex | |
| May 29, 2026 | S-3 | Shelf registration | DocumentIndex |
| May 22, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| May 19, 2026 | PRE 14C | DocumentIndex | |
| May 15, 2026 | 8-K | Material event | DocumentIndex |
| May 15, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 15, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 6, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| May 6, 2026 | 8-K | Material event | DocumentIndex |
| May 5, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| Apr 29, 2026 | 8-K | Material event | DocumentIndex |
| Apr 28, 2026 | 8-K | Material event | DocumentIndex |
| Mar 31, 2026 | 8-K | Material event | DocumentIndex |
| Mar 10, 2026 | 8-K | Material event | DocumentIndex |
| Mar 4, 2026 | 8-K | Material event | DocumentIndex |
| Mar 2, 2026 | EFFECT | DocumentIndex | |
| Feb 20, 2026 | POS AM | DocumentIndex | |
| Feb 17, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 13, 2026 | 8-K | Material event | DocumentIndex |
| Feb 13, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jan 29, 2026 | DEF 14C | DocumentIndex | |
| Jan 20, 2026 | PRE 14C | DocumentIndex | |
| Jan 12, 2026 | EFFECT | DocumentIndex | |
| Jan 5, 2026 | S-3 | Shelf registration | DocumentIndex |
| Dec 23, 2025 | 8-K | Material event | DocumentIndex |
| Dec 23, 2025 | 10-K | Annual report | DocumentIndex |
| Dec 17, 2025 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Dec 10, 2025 | 8-K | Material event | DocumentIndex |
| Dec 10, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Dec 1, 2025 | 8-K | Material event | DocumentIndex |
| Nov 14, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Oct 27, 2025 | 8-K | Material event | DocumentIndex |
| Oct 23, 2025 | 8-K | Material event | DocumentIndex |
| Sep 26, 2025 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Sep 19, 2025 | S-8 | Employee stock plan | DocumentIndex |